Bristol-Myers Squibb (NYSE:BMY) & CalciMedica (NASDAQ:CALC) Critical Contrast

CalciMedica (NASDAQ:CALC) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for CalciMedica and Bristol-Myers Squibb, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	0	0	2	0	3.00
Bristol-Myers Squibb	2	11	5	2	2.35

CalciMedica presently has a consensus target price of $18.00, suggesting a potential upside of 1,080.33%. Bristol-Myers Squibb has a consensus target price of $58.00, suggesting a potential upside of 19.19%. Given CalciMedica’s stronger consensus rating and higher probable upside, analysts clearly believe CalciMedica is more favorable than Bristol-Myers Squibb.

Risk and Volatility

CalciMedica has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares CalciMedica and Bristol-Myers Squibb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-164.24%	-103.53%
Bristol-Myers Squibb	-18.53%	13.93%	2.46%

Institutional & Insider Ownership

76.4% of Bristol-Myers Squibb shares are held by institutional investors. 41.5% of CalciMedica shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares CalciMedica and Bristol-Myers Squibb”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$34.36 million	($1.19)	-1.28
Bristol-Myers Squibb	$48.30 billion	2.05	-$8.95 billion	($4.42)	-11.01

CalciMedica has higher earnings, but lower revenue than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Summary

CalciMedica beats Bristol-Myers Squibb on 8 of the 14 factors compared between the two stocks.

About CalciMedica

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.